Insecticides India Ltd

Q4 FY26Fertilizers & Agrochemicals

Insecticides India Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹610

Market cap₹1.8K Cr

P/E14.7

Updated23 Aug 2026

Read4 min read

The short version

Kaeros brand sales expected to at least double in the current fiscal year and potentially continue doubling over the next 3-4 years. The company expects both top-line (revenue) and bottom-line (profit) growth to be positive in FY27, with visible results from Q1 itself.

From Insecticides India Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Kaeros brand sales expected to at least double in the current fiscal year and potentially continue doubling over the next 3-4 years.
Kaeros brand to contribute 5%-8% to overall volumes; company targeting double-digit growth overall.
Top line (revenue) and bottom line (profit) expected to show positive growth starting Q1 FY27, dependent on monsoon season.
Export business projected to grow from 5% to around 10% of total sales over next 2-3 years, particularly from CDMO and technical products.
Continued expansion and launches of new patented and premium products aimed at increasing contribution to B2C revenues, targeting 60%-70% share in 3-4 years.
Technical plant expansions at Dahej and Sotanala planned to increase in-house production capabilities by FY27, supporting growth.
Management is cautiously optimistic about growth given geopolitical and climate uncertainties but expects overall decent sales growth.

Profitability & Margins

The company expects both top-line (revenue) and bottom-line (profit) growth to be positive in FY27, with visible results from Q1 itself.
Targets double-digit volume growth driven by brands like Kaeros, which is expected to contribute 5-8% to volume.
Margins have crossed double digits in FY26, and there is optimism to improve margins further, though seasonal conditions heavily influence this.
Focus on premium/patented products, aiming to increase their share from 60-63% currently to 70% over 3-4 years, which supports better profitability.
EBITDA margin improved from 6.8% to 10.6% over recent years, with gross profit margin rising to 31.5%.
Finance costs expected to reduce by 25-30% in FY27, aiding profit growth.
Efforts on faster cash collections and reducing working capital cycle targeted to improve cash flows and profitability.
Cautious optimism maintained due to external factors like El Nino and geopolitical tensions affecting raw material prices and demand.

See what Insecticides India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex requirement going forward remains largely nominal or in the range of INR 25-30 crores, termed as maintenance capex after completing projects in FY27.
Manufacturing facilities at Sotanala and Dahej provide sufficient capacity headroom for future growth, ensuring scalability and operational flexibility.
At Dahej, a new building (L&T) has started manufacturing and is expected to breakeven and be profitable post-Diwali FY27.
Sotanala plant plans to start formulation around Diwali FY27; technical plant expected to start by March-April 2027.
Two buildings in Sotanala planned: first to start technical operations by early kharif 2027; second building construction to proceed based on market conditions.
Investment of about INR 94 crores made in new products from internal accruals, indicating strategic investment in product portfolio.
Ongoing partnerships and R&D initiatives indicate continuous investment in innovation and technology.

Top-ranked in Fertilizers & Agrochemicals

Ranked on what management guided this quarter

5x potential

1Anya Polytech &₹180 Cr

Rev 2Mar 1

2Dharmaj Crop Guard Ltd₹911 Cr

Rev 2Mar 2

3₹5.6K Cr

Rev 2Mar 3

4₹1.3K Cr

Rev 3Mar 1

5₹56.9K Cr

Rev 3Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The company utilized bank limits in the last fiscal, partly due to higher inventory levels and investments in new products (INR94 crores from internal accruals).
No external fundraising was done through regular course of business debt; investments were funded internally.
Management acknowledges the need to work on reducing inventory, investments, and faster cash collections.
Interest cost for FY27 is expected to reduce internally by 25%-30%, indicating controlled or reduced debt levels.
Capex requirement for future growth is largely nominal or around INR25-30 crores (maintenance capex post-FY27 projects).
No explicit mention of new equity fundraising; however, ESOPs have been introduced to attract and retain talent.
Overall, focus is on operational cash flow and internal accruals rather than fresh external debt or equity raising.

See what Insecticides India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details about the current or expected order book or pending orders for Insecticides India Limited.
However, the company mentions cautious optimism about demand for FY27, with improving pillar activity amid rising prices.
They highlight ongoing product launches and technology partnerships, including new products with Nissan and innovation through a joint venture with OAT.
Inventory levels were higher last fiscal due to investments in new products (~INR94 crores) and higher inventory holdings.
The company is actively working on improving cash collection and reducing days sales outstanding (DSO) to enhance liquidity.
Capex plans are largely maintenance-oriented (INR25-30 crores for FY27), indicating focus on sustaining operations rather than aggressive expansion.
Overall, while direct order book numbers aren't disclosed, the company signals steady order flow supported by new product pipelines and cautiously positive market outlook.

Insecticides India Ltd — Quarterly revenue & net profit

Revenue Net profit

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹385 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Insecticides India Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Indogulf Cropsciences Ltd (Q4 FY26)
Successful single order in Venezuela contributing approximately INR 4 crores in revenue, indicating active export orders. Key concall takeaways from Indogulf…
Rallis India Ltd (Q4 FY26)
Crop Protection B2C business growth excluding Soil & Plant Health (SPH) will be marginally positive to low single digit; SPH segment grew robustly at 27%. Key…
Punjab Chemicals & Crop Protection Ltd (Q4 FY26)
Overall volume growth in FY '26 was around 14%, primarily driven by new products. Key concall takeaways from Punjab Chemicals & Crop Protection Ltd's Q4 FY26…
Krishana Phoschem Ltd (Q4 FY26)
The Company has recently completed a significant capacity expansion: NPK/DAP capacity increased by 50% to 495,000 MTPA, SSP capacity at 120,000 MTPA, totaling…

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs UPL Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Insecticides India Ltd Q4 FY26 results?

What is Insecticides India Ltd share price analysis?

Insecticides India Ltd currently shows a neutral. The stock trades at a P/E of 14.7 with a market cap of ₹1,837 Cr. Investors should review the full earnings analysis for detailed insights.

Is Insecticides India Ltd planning capital expenditure?

Capex requirement going forward remains largely nominal or in the range of INR 25-30 crores, termed as maintenance capex after completing projects in FY27.

Keep Insecticides India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.